This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Champix® (varenicline tartrate) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Champix in Different Patient Types

Champix has been studied in a range of different patient types.1-4

No psychiatric history

With a psychiatric history

Patients with COPD

Patients with CVD

Champix offers greater odds of quitting vs. placebo for smokers with stable cardiovascular disease (CVD).3

For smokers with stable CVD, CHAMPIX offers:

  • Greater odds of quitting smoking at 12 weeks vs. placebo3 (47.0% vs. 13.9%; OR=6.11; 95% Cl: 4.18-8.93; p<0.0001) 
  • Greater odds of remaining abstinent at 1 year vs. placebo3 (19.2% vs. 7.2%; OR=3.14; 95% Cl: 1.93-5.11; p<0.0001)

Please refer to the Warnings and Precautions.

Champix and CVD adverse events

Adjudicated serious cardiovascular events occurring in ≥1% in either group5*

Champix

Placebo

n=353

n=350

During treatment (or 30-day period after treatment)

Non-fatal MI

1.1

0.3

Hospitalisation for angina

0.6

1.1

During non-treatment follow-up (up to 52 weeks)

Need for coronary revascularisation

2.0

0.6

Hospitalisation for angina

1.7

1.1

New diagnosis of PVD or admission for PVD procedure

1.4

0.6

Over the course of the 52-week study

Cardiovascular death

0.3

0.6

PVD: Peripheral Vascular Disease 
Ml: Myocardial Infarction 
* Death and serious cardiovascular events were adjudicated by a blinded committee. Some of the smokers requiring coronary revascularisation underwent the procedure as part of management of non-fatal Ml and hospitalisation for angina.

​​​​​​​Please refer to the summary of product characteristics for further information on the safety profile of Champix.


References
  1. Anthenelli RM. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507-2520.
  2. Tashkin DP, et al. Effects of varenicline on smoking cessation in patients with mild-moderate COPD. Chest. 2011;139(3):591-599.
  3. Rigotti NA et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. A randomised trial. Circulation. 2010;121: 221-2 29.
  4. Mills EJ, et al. Comparisons of high dose and combination nicotine replacement therapy, varenicline and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis. Ann Med. 2012;44:588-597.
  5.  CHAMPIX Summary of Product Characteristics
PP-CHM-GBR-3358. June 2021

Champix efficacy vs NRT

Read about how Champix compares to nicotine replacement therapies.

Champix efficacy data

Support material for Champix patients

Download support material for patients prescribed Champix.

Download

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No